Hey Daz, look at the bright side mate:
Not funding the vaccs anymore with possible indirect upside from the listing of the new company. Imagine funds raised from the intial IPO should keep the R&D going for the first few years.
As sobering the thought of funds to advance the TAVR R&D it will be interesting to see market reaction with postive updates/announcements on this and then, all well, interest from future partners.
I guess that leaves it up to the Adapt products/IP to carry the company meanwhile.
Lets see how the dust settles after June 30 th, interesting times.
Ann: MOU signed for Admedus Vaccines, page-75
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |